TC-G203 for Patients With GPC3-Positive Advanced Solid Tumors

Recruiting now · Early Phase 1

Conditions studied: Solid Cancer, GPC3 Positive Hepatocellular Carcinoma

In brief

This is a single-arm, open-label, dose-escalation clinical trial designed to evaluate the safety, tolerability, expansion, and persistence of TC-G203 in patients with GPC3-positive recurrent or metastatic solid tumors who have progressed after prior therapies. The primary objective is to determine the maximum tolerated dose (MTD), with a secondary aim to assess preliminary clinical efficacy in solid tumors.

Key facts

Study ID

NCT07242417

Run by

Beijing GoBroad Hospital

People needed

30

Starts

2025-12-18

Expected to finish

2027-11-01

Last updated by the study team

2026-01-21

Who can join

Age: 18 and older, up to 75. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Participants must voluntarily provide written informed consent.
• Aged 18-75 years (inclusive).
• Life expectancy ≥ 12 weeks.
• ECOG performance status 0-1.
• Failed or unsuitable for standard therapy.
• At least one measurable lesion per RECIST 1.1.
• GPC3-positive tumor confirmed by immunohistochemistry.
• Adequate organ and bone marrow function.
• Effective contraception required for participants of childbearing potential.
• Adequate venous access for leukapheresis.

You may not qualify if…

• Primary CNS malignancy or uncontrolled CNS metastases.
• Other malignancies within 5 years
• Active autoimmune disease or history of autoimmune disease.
• Immunodeficiency, including HIV positivity
• Bleeding disorders (inherited or acquired).
• Clinically significant cardiovascular disease.
• Active infection (including tuberculosis, hepatitis C, syphilis).
• Pregnant or breastfeeding women.
• Severe systemic or psychiatric illness.
• Prior cell or gene therapy.
• Severe drug hypersensitivity history.
• Investigator-assessed unsuitability for trial participation. -

Where it is running

• Beijing Gobroad Hospital — Beijing, Beijing Municipality, China (enrolling)
• GoBroad Healthcare Group — Beijing, Beijing Municipality, China

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.